Blanket Purchase Agreement 36F79719D0224-36E79719A0032

Horizon Therapeutics USA Inc. has been awarded a single-award Blanket Purchase Agreement (BPA) valued at $31.375 million by the Department of Veterans Affairs (VA) National Acquisition Center, effective from September 20, 2024, through October 29, 2025. This BPA, established under the GSA Schedule for Pharmaceuticals and Drugs (FSS-61-IB) with no set-aside designation, authorizes the VA and its Veterans Integrated Service Networks (VISNs) to place firm fixed-price delivery orders for specialty...

This Blanket Purchase Agreement (BPA), awarded to BioMarin Pharmaceutical Inc. on October 15, 2021, establishes a framework for the supply of Palynziq (pegvaliase-pqpz) to the Veterans Affairs (VA) system through the GSA Schedule 61-IB for Pharmaceuticals and Drugs. The contract carries a ceiling value of $151,685 and extends through October 14, 2026, with performance conducted from BioMarin's location in Novato, California. The award was made as a single-award, non-set-aside procurement under...

Bausch Health US LLC, a pharmaceutical and medical device manufacturer headquartered in Bridgewater, New Jersey, was awarded a single-award Blanket Purchase Agreement by the U.S. Department of Veterans Affairs (VA) National Acquisition Center on October 17, 2022. This indefinite delivery vehicle, valued at $530,000 with an ultimate completion date of October 16, 2026, was established under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries no...

Vifor (International) AG, a Swiss-based pharmaceutical manufacturer, was awarded a single-award Blanket Purchase Agreement by the Department of Veterans Affairs National Acquisition Center on June 25, 2024, for the supply of KORSUVA (difelikefalin), a prescription medication indicated for the treatment of pruritus in patients undergoing hemodialysis. The BPA carries a ceiling value of $150,000 and extends through June 24, 2026, operating under the Pharmaceuticals and Drugs Federal Supply...

Biocryst Pharmaceuticals Inc. was awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs National Acquisition Center on May 19, 2021, with a $10 million ceiling value and an ultimate completion date of May 18, 2026. This procurement vehicle, established under the Federal Supply Schedule 61-IB for Pharmaceuticals and Drugs, facilitates the delivery of two specialized pharmaceutical products: RAPIVAB (peramivir) for influenza treatment and ORLADEYO...

This Blanket Purchase Agreement was awarded by the Department of the Army Medical Command to Nephron Sterile Compounding Center LLC on March 1, 2020, with a potential value of $2.5 million. The BPA is for specialized compounded intravenous solutions with no set-aside used. The period of performance extends through the last date to order of September 30, 2023. The BPA facilitates recurring orders for specific pharmaceutical products and supplies, including Phenylephrine HCI Injection,...

Recordati Rare Diseases Inc. was awarded a single-award Blanket Purchase Agreement by the Department of Veterans Affairs' National Acquisition Center on July 13, 2021, with an ultimate completion date of July 12, 2026. The contract carries a ceiling value of $3.16 million and operates under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) without set-aside designations. This BPA establishes a firm fixed-price procurement vehicle for five specialized orphan pharmaceutical...

This Blanket Purchase Agreement, awarded to Grifols USA LLC on May 1, 2022, establishes a single-award indefinite delivery vehicle for the procurement of PROLASTIN-C, an alpha1-proteinase inhibitor indicated for treatment of alpha1-antitrypsin deficiency. The contract carries a ceiling value of $107.5 million with an ultimate completion date of April 30, 2027, and is funded through the National Acquisition Center, a civilian federal agency. As a firm fixed-price contract awarded without...

The Blanket Purchase Agreement was awarded as a single-award contract by the Department of Veterans Affairs National Acquisition Center on April 14, 2022. The agreement is with Calliditas Therapeutics US Inc. to provide TARPEYO for a potential value of $1,750,000.00. TARPEYO is a treatment for the uncontrolled proteinuria in adult patients with primary immunoglobulin A nephropathy. As a single-award BPA with no set-aside, Calliditas Therapeutics will serve as the sole provider of this...

This Blanket Purchase Agreement, awarded on February 7, 2023, by the National Acquisition Center to Hikma Pharmaceuticals USA Inc. (formerly West-Ward Pharmaceuticals) with a ceiling value of $38.5 million, provides a single-award indefinite delivery vehicle for the procurement of sodium oxybate through December 17, 2025. No small business set-aside was utilized for this award. Sodium oxybate, marketed under the brand name XYREM, is a controlled pharmaceutical product used primarily in the...